NS100 Neuromodulation Therapy
by NeuroDynamics Global
Our FDA-cleared neuromodulation therapy is designed to help reduce chronic pain associated with painful diabetic neuropathy through a 20-day temporary protocol.
Device Specifications
The NeuroDynamics Global system is engineered for clinical efficacy and patient comfort.
Peripheral Nerve Electrical Stimulation
NeuroDynamics Global delivers targeted electrical stimulation to peripheral nerves to help modulate pain signals associated with painful diabetic neuropathy.
20-Day Temporary Protocol
Unlike permanent implants, the NeuroDynamics Global device is worn for a defined 20-day period and then removed in a simple office procedure.
FDA-Cleared Class II Device
NeuroDynamics Global has received FDA clearance as a Class II medical device for the treatment of chronic pain due to PDN.
Minimally Invasive Design
Designed for implantation by trained healthcare providers, with minimal disruption to practice workflow.
20-Day Protocol Timeline
A temporary therapy designed for meaningful, durable relief.
Device Implantation
Minimally invasive surgical procedure under topical anesthesia. Patient receives training on device use.
Therapy Initiation
Patient wears device continuously. Stimulation parameters adjusted as needed.
Active Treatment
Ongoing therapy delivery. Patient continues normal daily activities.
Therapy Completion
Final days of stimulation protocol. Follow-up assessment scheduled.
Device Removal
Simple in-office removal procedure. Patient outcomes evaluated.
Treatment Progress
Clinical Workflow
A streamlined process designed for real-world clinical settings.
Patient Identification
Identify PDN patients who may benefit from NeuroDynamics Global therapy
Coverage Verification
Verify insurance coverage and obtain prior authorization
Procedure Scheduling
Schedule implantation procedure and patient training
Device Implantation
Perform implantation under topical anesthesia
20-Day Therapy
Patient wears device; clinical support as needed
Device Removal
Remove device and document patient outcomes
Full operational support at every step
NeuroDynamics Global provides training, clinical liaison support, and revenue cycle management assistance to help ensure smooth implementation.
Request Program InformationA neuromodulation pathway that targets pain and glucose regulation
NS100 is designed to engage multiple biologic pathways involved in glucose regulation while simultaneously treating painful diabetic neuropathy. Individual results vary.
Increases insulin secretion
Targeted neuromodulation is associated with enhanced endogenous insulin release in observational study data.
Reduces hepatic glucose production
Engagement of autonomic pathways is associated with downregulation of hepatic glucose output.
Improves insulin sensitivity
Combined autonomic and peripheral effects are associated with improved cellular response to insulin.
Mechanistic descriptions reflect observed pathways in published and ongoing NS100 research; not a claim of cure or disease modification. See clinical research abstracts for study details.
Indications for Use
The NeuroDynamics Global device is indicated for the treatment of chronic pain associated with painful diabetic neuropathy (PDN). The device should be used under the direction of a licensed healthcare provider trained in its use.
Important Safety Information
The NeuroDynamics Global device is an FDA-cleared Class II medical device. As with any medical procedure, there are potential risks. Patients should discuss all risks and benefits with their healthcare provider. Full prescribing information is available upon request.
Ready to bring NeuroDynamics Global to your practice?
Contact us for detailed clinical information, training requirements, and program implementation support.